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Abstract
Background: Current clinical procedures for rotator cuff tears need to be improved, as a high rate of failure is still
observed. Therefore, new approaches have been attempted to stimulate self-regeneration, including biophysical
stimulation modalities, such as low-frequency pulsed electromagnetic fields, which are alternative and non-invasive
methods that seem to produce satisfying therapeutic effects. While little is known about their mechanism of action,
it has been speculated that they may act on resident stem cells. Thus, the purpose of this study was to evaluate the
effects of a pulsed electromagnetic field (PST®) on human tendon stem cells (hTSCs) in order to elucidate the
possible mechanism of the observed therapeutic effects.
Methods: hTSCs from the rotator cuff were isolated from tendon biopsies and cultured in vitro. Then, cells were
exposed to a 1-h PST® treatment and compared to control untreated cells in terms of cell morphology, proliferation,
viability, migration, and stem cell marker expression.
Results: Exposure of hTSCs to PST® did not cause any significant changes in proliferation, viability, migration, and
morphology. Instead, while stem cell marker expression significantly decreased in control cells during cell culturing,
PST®-treated cells did not have a significant reduction of the same markers.
Conclusions: While PST® did not have significant effects on hTSCs proliferation, the treatment had beneficial effects on
stem cell marker expression, as treated cells maintained a higher expression of these markers during culturing. These
results support the notion that PST® treatment may increase the patient stem cell regenerative potential.
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Background
Rotator cuff tendinopathy is a degenerative process
causing pain and disability [1, 2]. Generally, a non-
operative management is regarded as the first-line
treatment prior to a surgical intervention [3]. None-
theless, given the rather inconsistent results of either
approaches, new strategies have been explored, espe-
cially in the rising field of tissue engineering [4–10].
The discovery that also the human rotator cuff
tendons possess a reservoir of progenitor cells, the
human tendon stem cells (hTSCs), has clearly opened
up new perspectives for developing novel therapies
[11–15]. In fact, hTSCs could be used in cell therapy
approaches and, maybe most importantly, they could
potentially be activated in situ, in order to regenerate
the affected tendon without the need of harvesting
them from biopsies, growing them in vitro, and re-
injecting them. Actually, growing evidences seem to
support the notion that when adult stem cells are
injected to regenerate a tissue, like the heart or a
tendon, only a negligible fraction of cells can survive
and differentiate into the desired cell phenotype [16].
In fact, the majority of the injected stem cells simply
secrete factors (most of them still unknown) that
stimulate resident progenitor cells, which are really
the ones that repair the affected tissue. Therefore, in
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the last few years, researchers have focused their
attention on identifying these secreted factors, to use
them instead of injecting cells [16–19]. On the other
hand, other approaches have been attempted to
stimulate self-regeneration, including biophysical
stimulation modalities, such as low-frequency pulsed
electromagnetic fields (PEMFs), which are alternative
and non-invasive methods that seem to produce satis-
fying therapeutic effects also on a wide range of
orthopedics diseases, including osteoarthritis [20, 21],
non-united fractures [22, 23], failed arthrodesis [24],
and soft tissue injuries [25]. However, little is known
about the real mechanism by which these effects are
obtained. A plausible explanation is that these electro-
magnetic fields can stimulate the self-healing
processes of the affected tissues by activating their
resident stem cells. Among others, a specific low-
frequency pulsed electromagnetic field (commercially
known as PST®, by Global Munich Germany) is a
modification of other low frequency PEMFs, and it
has been developed to ideally correspond to the
body’s own stimulatory energy parameters. The PST®
device consists in a cylindrical solenoid in which the
patient can insert the affected area (including the
shoulder) during treatment. It employs direct current
with unidirectional low frequencies in the range of
10–30 Hz. The waveform is quasi-rectangular, with
measured field strengths predominantly in the 0.5–1.5
mT range. Various frequency-amplitude combinations
are automatically switched over and transmitted under
continuous control during the treatment period,
which is generally set to 1 h.
Based on these premises, the aim of this study was to
evaluate the effects of PST® on primary cultures of
hTSCs and to test whether the application of this pulsed
electromagnetic field could alter their phenotype, for in-
stance by increasing their stemness and/or their regen-
erative capacity, with the ultimate goal of clarifying the
mechanism of the observed therapeutic effects.
Methods
Isolation, characterization, and culture of human tendon
stem cells
Human tendon stem cells (hTSCs) were isolated from
supraspinatus tendon specimens collected during
arthroscopic rotator cuff repair, according to a previ-
ous procedure (Fig. 1a) [11]. The study protocol has
been approved by the Hospital Ethical Committee
(authorization number 2642; Sept 19, 2011; ASL
Milano 2, Melegnano, Milan) and patients received
and signed an informed consent. Briefly, samples from
supraspinatus tendons (4–8 mm wide) were collected
from six patients, kept in HypoThermosol (BioLife
Solutions) at 4 °C, and processed separately within
24 h, according to the procedure described below.
Samples were washed with phosphate-buffered saline
(PBS) (Euroclone), cut into small pieces, and digested
for 90 min with collagenase type I (3 mg/mL;
Worthington) and dispase (4 mg/mL; Gibco, Life
Technologies) in PBS at 37 °C. After centrifugation, cell
pellets were resuspended in the following culture medium:
α-Minimal Essential Medium (α-MEM) (Sigma-Aldrich)
supplemented with 2 mM glutamine (Euroclone), 1 %
antibiotic-antimycotic mixture (Euroclone) and 20 % (v/v)
fetal bovine serum (FBS) (HyClone, Thermo-Fisher
Scientific). Cells were then filtered with a cell strainer
(70 mM; BD Falcon) and plated in 150-cm2 dishes.
Adherent cells were cultured at 37 °C with a humidi-
fied atmosphere of 5 % CO2. The medium was chan-
ged every 2–3 days. The isolated hTSCs at passage
three were characterized by flow cytometry for the
expression of key stem cell markers and to test the
level of contamination with other cell types (Additional
file 1: Figure S1). Flow cytometry analysis was per-
formed on 1 × 105 cells/sample. Briefly, aspecific bind-
ing sites were blocked with a blocking solution (50 %
1x PBS, 50 % FBS) for 30 min at room temperature,
and washed twice with PBS. Cells were stained with
fluorochrome-conjugated mouse anti-human anti-
bodies at the optimal concentration (1:20 dilution) in
PBS for 10 min at 4 °C, and washed twice with PBS
at 4 °C. Cell characterization was performed using the
following antibodies: αCD9 FITC, αCD73 FITC,
αHLA-DR FITC, αCD13 PE, αCD29 PE, αCD44 PE,
αCD45 PE, αCD90 PE, αCD105 PE, αCD106 PE,
αCD34 PerCP-eFluor710, αCD166 PerCP-eFluor710,
and αSSEA-4 PE (all from eBioscience); αLineage
Cocktail FITC, αCD18 PE, αCD146 PE, and αStro-1
Alexa Fluor 647 (all from BioLegend); and αCD117 PE
(Miltenyi Biotech). The respective isotype antibodies were
used as controls. Samples were acquired with a Navios
flow cytometer (Beckman Coulter), and data were proc-
essed with Kaluza 1.2 software (Beckman Coulter). Cells
at passage three were used for all the experiments.
Cell differentiation
hTSCs were induced to differentiate toward adipocytes,
osteoblasts, and chondroblasts in vitro to test for their
multi-lineage potential, according to the following
procedures (Fig. 1b).
Adipogenic differentiation
hTSCs were plated at a concentration of 3 × 104 cells/cm2
in normal growth medium, and then switched to DMEM-
low glucose (Sigma-Aldrich), 10 % FBS (HyClone, Thermo-
Fisher Scientific), 4 mM L-glutamine (Euroclone), 1 %
antibiotic-antimycotic mixture (Euroclone), with the
addition of the mesenchymal stem cell adipogenesis
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kit (Millipore) for 21 days, according to the manufac-
turer’s instructions. At day 21, Oil Red O solution
(Millipore) was used to stain lipid droplets of derived
adipocytes, according to the manufacturer’s procedures.
All photomicrographs were acquired with an Axiovert 40
microscope (Zeiss) equipped with a Moticam 2300 camera
(Motic). The adipogenic medium was changed every
2–3 days.
Osteogenic differentiation
hTSCs were plated at a concentration of 3 × 104 cells/
cm2 in normal growth medium, and then switched to
the osteogenesis induction medium, which was consti-
tuted of DMEM-low glucose (Sigma-Aldrich), 10 %
FBS (HyClone, Thermo-Fisher Scientific), 4 mM L-
glutamine (Euroclone), 1 % antibiotic-antimycotic
mixture (Euroclone), supplemented with 0.1 μM dexa-
methasone, 50 μg/ml L-ascorbic acid-2-phosphate,
and 10 mM β-glycerophosphate (all reagents from
Sigma-Aldrich) for 17 days. At day 17, Alizarin Red
solution (Millipore) was used to detect calcium
deposition in derived osteoblasts, according to the
manufacturer’s instruction. All photomicrographs were
acquired with an Axiovert 40 microscope (Zeiss)
equipped with a Moticam 2300 camera (Motic). The
osteogenic medium was changed every 2–3 days.
Chondrogenic differentiation
hTSCs were maintained in a 3D culture by growing them
in cell pellets (1 × 106 cells/pellet) in AdvanceSTEM chon-
drogenic differentiation medium (HyClone, Thermo
Scientific), according to the manufacturer’s instruc-
tions. After 28 days of differentiation, matrix depos-
ition by derived chondroblasts was detected with
Alcian Blue staining (Sigma-Aldrich), according to the
manufacturer’s instruction. All photomicrographs were
Fig. 1 Isolation and characterization of human tendon stem cells (hTSCs). a Schematic representation of the protocol used to isolate hTSCs. b In
vitro differentiation of hTSCs toward the adipogenic, the osteogenic, and the chondrogenic phenotypes. Lipid intracellular droplets (red) in the
adipocytes were stained with Oil Red O solution. Alizarin Red-S staining revealed the presence of calcium deposits 2016 (yellowish-brown). Alcian
Blue staining detected/assessed the proteoglycan content. Typical results are shown. Original magnification x10. c Gene expression of stem cell
marker (Oct4, KLF4, and Nanog) by Real-Time PCR in hTSCs and human dermal fibroblasts (hDFs). Data are expressed as means ± SD of three
different experiments
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acquired with an Axiovert 40 microscope (Zeiss) equipped
with a Moticam 2300 camera (Motic). The chondrogenic
medium was changed every 2–3 days.
PST® device and cell treatments
The PST® treatment was performed by placing the cell
culture plate at the center of PST® device in order to
have the magnetic field vector perpendicular to the plate
surface (Fig. 2). hTSCs were plated at a concentration of
2.6 × 103 cells/cm2 in normal growth medium. Twenty-
four hours after seeding, cells were either treated with
PST® for 1 h (PST), or were kept outside the incubator
for the same amount of time (control) (Fig. 2c). PST and
control cells were then returned to the incubator and
grown for other 10, 24, or 48 h.
Cell morphology and proliferation experiments
To assess whether PST® stimulation could affect
hTSCs phenotype, cell morphology was examined
with a phase-contrast microscope (Axiovert 40 CFL,
Zeiss, equipped with a Moticam 2300 camera, Motic)
after 0, 10, 24, and 48 h of PST® exposure. For cell
viability analyses, hTSCs were subjected to PST®
stimulation, as described before. PST and control cells
were analyzed at each time point after harvesting with
Trypsin-EDTA solution (Sigma-Aldrich) by counting with
a Countess Cell Counter (Invitrogen, Life Technologies),
according to the manufacturer’s procedure. Cell via-
bility was determined by trypan blue dye exclusion
assay. The number of viable cells in each sample was
expressed as a percentage of the total untreated cells
number at day 0. All assays were carried out in tripli-
cates for each sample.
Cell viability by MTT assay
hTSCs were plated in 12-well plates (1 × 104 cells/well) and
were subjected to PST® stimulation, as previously described.
At each time point (0, 10, 24, and 48 h), two hours before
Fig. 2 Pulsed Signal Therapy® (PST®). a A typical setting for PST® treatment of patients with rotator cuff tendinopathy. b A typical
experimental setting for PST® treatment of hTSCs. The white arrow points to the culture dish positioned at the center of the solenoid.
c Schematic representation of the experimental setup: twenty-four hours after seeding, hTSCs were divided into two groups, either
treated with PST® for 1 h (PST) or kept outside the incubator for the same amount of time (control). Then, PST and control cells were
returned to the CO2 incubator and cultured for 10, 24, and 48 h for successive analyses
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collection, the reconstituted 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl-2H-tetrazolium bromide (MTT) (5 mg/ml in
PBS; Sigma) was added to the medium (10 % of the
final volume). Following a 2-hour incubation at 37 °C,
PST and control cells were lysed by adding an amount
of MTT Solubilization Solution equal to the original
culture medium volume, gently pipetting to completely
dissolve the MTT formazan crystals. The MTT reduc-
tion was spectrophotometrically measured at a wave-
length of 570 nm.
Cell migration by wound-healing assay
Wound-healing assay was performed as previously
described [26]. hTSCs were grown to confluence in 6-
well plates and were subjected to PST® stimulation or
were kept outside the incubator for the same amount
of time (controls). A sterile P200 pipet tip was used
to create a scratch across the cell monolayer. Then,
cultures were washed once with 1 ml of growth
medium to remove the damaged and detached cells.
After replacing the medium, hTSCs were allowed to
grow for 48 h. At different time points, cell cultures
were examined with a phase-contrast microscope
(Axiovert 40 CFL, Zeiss, equipped with a Moticam
2300 camera, Motic) and images of the same scratch
fields were acquired at time 0 and after 5, 20, 24, and
30 h from the scratch. The gap area between the cells
was calculated in each acquired image using software
ImageJ. The migration rate was based on the measure
of the recovered wound area (experimental data
expressed in percentage). All assays were carried out
in triplicates for each sample.
Cell apoptosis analysis
Apoptosis was measured by flow cytometry on PST
and control cells before a 1-h PST® treatment and
then 10, 24 and 48 h post treatment, using Annexin
V-FITC Apoptosis detection kit (Enzo Life Sciences),
according to the Manufacturer’s protocol. Briefly,
adherent cells were trypsinized, washed in PBS by
gentle shaking, and resuspended with 200 μl of a
specific Binding Buffer (10 mM HEPES/NaOH,
pH 7.4; 140 mM NaCl; 2.5 mM CaCl2) containing
5 μl of annexin V-FITC. After incubation for 10 min
in the dark at room temperature, cells were washed
in PBS, resuspended in 190 μl of Binding Buffer, and
then stained with 10 μl Propidium Iodide (20 μg/ml).
Samples were acquired with a Navios flow cytometer
(Beckman Coulter), and analyzed using Kaluza 1.2
software (Beckman Coulter).
Gene expression analysis
Stem cell, tendon-related marker, and vascular endothe-
lial growth factor expression was tested by Real-Time
PCR. Total RNA was extracted from PST and control
cells at 0, 10, 24 and 48 h using TRIzol®Reagent
(Ambion, Life Technologies) and 1 μg of extracted
RNA was reverse transcribed to cDNA using the
iScript cDNA synthesis kit (BioRad), according to the
Manufacturer’s instructions. Real-Time PCR was per-
formed in a 96-well plate with 10 ng of cDNA as
template, 0.2 μM primers, and 1× Power SYBR®
Green PCR Master Mix (Applied Biosystems, Life
Technologies) in a 20 μl final volume per well, using
a StepOnePlus™Real-Time PCR System (Applied
Biosystems). The mRNA levels of octamer-binding
transcription factor 4 (Oct4), kruppel-like factor 4
(KLF4), Nanog homeobox (Nanog), Tenascin C, collagen
type I alpha-1 (COL1A1), and vascular endothelial growth
factor (VEGF) were assessed. Somatostatin-14 peptide
(S14) was used as the housekeeping gene in quantitative
analysis. Primer sequences: S14, forward 5′-GTGTGA
CTGGTGGGATGAAGG-3′ and reverse 5′-TTGATGT
GTAGGGCGGTGATAC-3′; Oct4, forward 5′-AGGA
GAAGCTGGAGCAAAA-3′ and reverse 5′-GGTCGAA
TACCTTCCCAAA-3′; KLF4, forward 5′-GACTTCCCC
CAGTGCTTC-3′ and reverse 5′-CGTTGAACTCCT
CGGTCTC-3′; Nanog, forward 5′-GGTCCCAGTCAA
GAAACAGA-3′ and reverse 5′-GAGGTTCAGGATGT
TGGAGA-3′; Tenascin C, forward 5′-CGGGGCTATA
GAACACCAGT-3′ and reverse 5′-AACATTTAAGTT
TCCAATTTCAGGTT-3′; COL1A1, forward 5′-GGGAT
TCCCTGGACCTAAAG-3′ and reverse 5′-GGAACAC
CTCGCTCTCCA-3′; VEGF, forward 5′-CAACATCAC
CATGCAGATTATGC-3′ and reverse 5′-TCGGCTTG
TCACATTTTTCTTGT-3′.
Amplification protocol: an initial denaturation at 95 °C
for 3 min, followed by 40 cycles of 5 s each at 95 °C and
30 s at 57 °C. Relative quantification of target genes was
performed in triplicates, analyzed using the 2−ΔΔCt
method and normalized to the corresponding S14
values.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
v 6.0 software (GraphPad Software Inc.). Data were typ-
ical results from three replicate experiments for each of
the four patients-derived cell lines, and were expressed
as the mean ± standard deviation (SD). Paired compari-
sons were performed by two-tailed t test. When data
was not normally distributed, the Wilcoxon matched-
paired test was performed. The significance level was set
at p value lower than 0.05.
Results
To mimic the standard PST®-treatment procedure on
patients’ rotator cuff (Fig. 2a), hTSCs cells were
cultured in 150 mm2 dishes, placed for 1 h inside the
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PST® solenoid (Fig. 2b), and then returned to the
CO2 incubator (Fig. 2c), as described in the Methods.
Control hTSCs were kept outside the incubator for
1 h during the PST®-treatment time.
Isolation, characterization, and culture of hTSCs
Isolation of hTSCs was performed according to the proto-
col described in the Methods section and summarized in
Fig. 1a.
hTSCs were cultured to passage three, and then sub-
jected to immunophenotyping by flow cytometry, reveal-
ing positivity for mesenchymal antigens CD73, CD90,
CD105, CD166, CD106, and CD146 and negativity for
hematopoietic antigens, CD19, CD34, CD45, and HLA-
DR, as expected (Additional file 1: Figure S1A). As shown
in Additional file 1: Figure S1B, hDFs were phenotypically
characterized by flow cytometry as controls for compari-
son with hTSCs, revealing that the immunophenotype of
hDFs does not significantly differ from that of hTSCs.
Both cell populations resulted positive for mesenchy-
mal lineage markers like CD73, CD90 and CD105, and
negative for hematopoietic lineage markers like CD19,
CD34, CD45 and HLA-DR (Additional file 1: Figure S1).
To confirm their stemness, isolated hTSCs were
induced to differentiate in vitro toward adipocytes,
osteoblasts, chondrocytes by treatment with the proper
differentiation media. Results confirmed that hTSCs
could be efficiently induced to differentiate towards
these cell phenotypes (Fig. 1b).
Conversely, analysis of stem cell markers Oct4, KLF4
and Nanog, measured by quantitative Real-Time PCR,
confirmed the expression of the genes in hTSCs, while
hDFs showed almost undetectable levels, as expected for
terminally differentiated cells (Fig. 1c).
Effects of PST® treatment on hTSCs morphology,
proliferation, and viability
Cell morphology was analyzed by phase contrast micros-
copy before a 1-h PST® treatment and then 10, 24, and
48 h post treatment. Results showed no noticeable differ-
ences between PST and untreated control cells at all time
points (Fig. 3a). In addition, proliferation analyses revealed
an exponential cell growth in both groups, with no signifi-
cant differences at all time points (Fig. 3b, p > 0.05). These
results were confirmed by MTT cell metabolic activity
assay, where no significant differences between PST and
control cells could be observed at all time points (24, 48,
and 72 h) (Fig. 3c).
Effects of PST® treatment on hTSCs migration
In order to evaluate the effects of PST® treatment on the
repairing capacity of hTSCs, an in vitro wound-healing
assay was performed. The wound was completely closed
in all conditions within 45–48 h, and PSTand control cells
showed a similar rate of wound closure (a representative
image of PST and control hTSCs moving into the wound
space is shown in Fig. 3d for both groups at 0 and 24 h
after scratching). Quantitative analyses indicated no sig-
nificant differences in cell migration velocity between PST
and control cells at all-time points (p > 0.05, Fig. 3d, e).
Effects of PST® treatment on hTSCs apoptosis
Apoptosis was measured by flow cytometry before a 1-h
PST® treatment and then 10, 24 and 48 h post treatment
using Annexin V-FITC, and compared to control un-
treated cells at the same time points (Fig. 4). Results re-
vealed no significant apoptosis in all tested samples
(always below 1 %), with no statistically significant differ-
ences between PST- and control- groups.
Effects of PST® treatment on hTSCs stem cell/tendon-
related markers and VEGF
The relative mRNA levels of stem cell markers Oct4,
KLF4 and Nanog were measured by quantitative Real-
Time PCR analyses before a 1-h PST® treatment and
then 10, 24 and 48 h post treatment, and compared to
the initial expression values before treatment (Fig. 5a–c).
A significant reduction in stem cell marker expression at
48 h was observed in the control group, as compared to
the PST cells. Oct4, KLF4 and Nanog expressions were
reduced of 44 ± 7 % (p = 0.009), 33 ± 7 % (p = 0.01) and
49 ± 36 % (p = 0.04), respectively (Fig. 5a–c). Otherwise,
stem cell marker expression of PST group was similar to
that of untreated cells (p > 0.05). Oct4 expression at 10 h
in the PST group was also significantly reduced com-
pared to the untreated cells of 41 ± 13 % (p = 0.03)
(Fig. 5a).
Tenascin C and COL1A1 expression levels were com-
parable to untreated cells (day 0) at each time point in
both groups (p > 0.05) (Fig. 5d, e). COL1A1 expression
at 48 h in the PST group was also significantly reduced
compared to the untreated cells of 33 ± 19 % (p = 0.04)
(Fig. 5e).
Analysis of the VEGF, a key marker involved in vascu-
logenesis and angiogenesis, by Real-Time PCR revealed
no significant differences between the PST and control
group in VEGF mRNA expression as compared to
untreated cells (day 0) at each time point in both groups
(p > 0.05) (Fig. 5f ).
Discussion
The possibility of activating tendon healing through
electromagnetic stimulation has become increasingly
popular. However, little is known about the origin of
the beneficial effects that have been observed, al-
though the possibility of stem cells involvement in
the process has been often speculated. Thus the main
goal of this work was to evaluate the effects of a
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pulsed electromagnetic field, PST®, on human tendon
stem cells isolated from patients undergoing surgeries.
A critical issue that had to be taken into consider-
ation in designing this in vitro study was to maximize
the cell exposure to the field. In fact, several authors
have shown that the electrical field depends on the
cross-sectional area of the culture media seen by the
magnetic field [27–29]. Therefore, in this study, the
PST® treatment was performed by placing the cell
culture plate at the center of the PST® device, parallel
to the ground, in order to have the magnetic field
vector perpendicular to the plate surface.
The first finding of this study was that the PST® treat-
ment (0.5–1.5 mT, 10–30 Hz, for 1 h, as in the standard
treatment administered to patients) had no cytotoxic ef-
fects on hTSCs in terms of cell viability, proliferation,
and migration. These results are in agreement with other
studies made with different pulsed electromagnetic
fields on various cell types, including human tenocytes
[30–33]. However, these studies reported contrasting
results on cell proliferation, which was sometimes sig-
nificantly increased upon stimulation [31–35]. None-
theless, the time of treatment, often exceeding twelve
consecutive hours, could be considered rather incom-
patible with a realistic therapeutic application. Also,
changes in cell morphology, size and orientation were
occasionally reported upon pulsed magnetic field
stimulation [28]. Still, in our experimental settings,
hTSCs morphology was not altered by PST® exposure.
Then, we tested the effects of PST® treatment on stem
cell and tendon-related marker expression. Along this
line, it has been observed that a single prolonged
Fig. 3 Effects of PST® treatment on hTSCs morphology, proliferation, viability, and migration. a Phase-contrast microphotographs (original
magnification x10, at 48 h after treatment), b cell growth curves of hTSCs before a 1-h PST® treatment and at 10, 24, and 48 h post treatment.
c MTT assay of hTSCs before a 1-h PST® treatment and at 24, 48, and 72 h post treatment Control cells were cultured outside the incubator for
1 h during PST® treatment. d, e Effect of PST® treatment on hTSCs migration. d Representative time-lapse migration images of PST and control
cells. Images were acquired at 0 and 24 h in in vitro wound-healing assay. Original magnification x5. e The migration rate was measured by
quantifying the total area of the wounded region lacking cells. The average percentages of recovered area obtained from three different
experiments at 5, 10, 20, 24, and 30 h post treatment, as compared to control cells. All experiments were performed in triplicates. Error bars
show the mean ± SD of three different experiments. Only p-values <0.05 are indicated, as compared to control cells
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Fig. 4 Effects of PST® treatment on apoptosis. Flow cytometric analysis of hTSCs survival rate before a 1-h PST® treatment and then 10, 24 and
48 h post treatment (right panel), as compared to control cells (left panel), through double staining with Annexin V-FITC and PI. Early apoptotic
cells (Annexin V-positive/PI-negative) are localized in the lower right region, late apoptotic and necrotic cells (Annexin V-positive/PI-positive) in the
upper regions, and vital cells (double negative) in the lower left region
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exposure to PEMFs (8 to 12 h) can positively influence
the expression of tendon-specific markers (COL1A1
and SCX) in a dose-dependent manner [31, 32]. How-
ever, a 1-h PST® treatment on hTSCs had no signifi-
cant effects on the expression of Tenascin C and
COL1A1. Similar results were observed by Du et al.
on human umbilical cord MSCs, where a 2-h treat-
ment per day for 15 days did not cause any significant
changes in the expression of several tendon and osteo-
genic markers, including COL1A1 [36]. On the other
hand, PST® treatment seems to have a positive effect
on stem cell marker expression. In fact, while the ex-
pression of stem cells markers (OCT4, Nanog, and
Klf4) significantly decreased in control hTSCs, as expected
during a 48 h in vitro cell culture, PST® treatment seems
to maintain hTSCs in a more undifferentiated state, as no
significant decrease in the same stem cell markers could
be observed for 48 h after the 1-h treatment. These
findings are in agreement with previous literature re-
ports on other stem cells, which showed that the gene
expression profiles regulating osteogenic and neuronal
differentiation were altered after subjecting cells to an
electromagnetic field treatment [37, 38]. Regarding the
variability of stem cell marker expression in the PST
group, this could be due to the fact that stem cells iso-
lated from different patients were used in the study. In
fact, high inter-individual differences in stem cell re-
sponse could be due to a variety of parameters, includ-
ing the patient’s age, co-morbidities, or the different
degree of tendon injury. This could be also the cause
of the discrepancies observed in the literature, where
electromagnetic fields of different types were used on
a variety of cells (differentiated or stem cells), which
could indeed respond very differently to the treatment.
Moreover, PST®, in contrast to other PEMF, uses a
unique rectangular pulsed as the stimuli, which varies
in amplitude and frequency [39]. Therefore, it is diffi-
cult to compare the results of the current study with
previous reports, as many parameters, including the
time of treatment, are different.
Finally, we tested whether the PST® treatment would
increase VEGF expression, as the beneficial effects could
be due to reduced inflammation and increased neovas-
cularization. However, we could not detect any signifi-
cant changes in VEGF expression upon PST® treatment
on hTSCs, which doesn’t rule out that the treatment
could have effects on other cell types, as endothelial
cells, which are more likely to be involved in the
process.
Conclusions
In conclusion, we found that a 1-h exposure to pulsed
electromagnetic field PST® did not cause any significant
changes in human tendon stem cell proliferation and
morphology. Nonetheless, the treatment seems to have
beneficial effects on stem cell marker expression, as
treated cells maintain a higher expression of these
markers during the in vitro culturing, supporting the
preservation of a more undifferentiated status. Clearly,
the next step would be to test whether these effects
could be observed in vivo in an animal model, which is
currently undergoing in our laboratories.
Fig. 5 Effects of PST® treatment on stem cell marker (Oct4, KLF4, and Nanog) (a–c), tendon marker (Tenascin C and COL1A1) (d, e), and VEGF (f)
expression by Real-Time PCR before a 1-h PST® treatment and at 10, 24, and 48 h post treatment, as compared to untreated controls. Values are
expressed as fold-changes relative to untreated cells at time zero (dotted line set at 1). Data are expressed as means ± SD of three different experiments.
p-values were calculated using T student test or Wilcoxon test according to data distribution. Only p-values <0.05 are indicated: *, p < 0.05; **, p < 0.01
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dermal fibroblasts (hDFs) and human tendon stem cells (hTSCs) by flow
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